Skip to main content
Top
Published in:

Open Access 04-07-2024 | Gentamicin | Brief Report

Gentamicin combination treatment is associated with lower mortality in patients with invasive listeriosis: a retrospective analysis

Authors: Jan P. Sutter, Lorenz Kocheise, Jan Kempski, Martin Christner, Dominic Wichmann, Hans Pinnschmidt, Stefan Schmiedel, Ansgar W. Lohse, Samuel Huber, Thomas Theo Brehm

Published in: Infection | Issue 4/2024

Login to get access

Abstract

Purpose

Listeria monocytogenes causes severe bacterial infections with the highest mortality rate among foodborne pathogens in Europe. Combination treatment with ampicillin and gentamicin is recommended for invasive manifestations. However, evidence to support this treatment approach remains limited due to a lack of randomised controlled trials. To explore this critical issue further, we conducted this retrospective, single-center study.

Methods

We identified all patients hospitalized with invasive listeriosis at the University Medical Center Hamburg-Eppendorf between 2009 and 2020 and analyzed the effect of gentamicin combination treatment versus monotherapy on 90-day mortality.

Results

In total, 36 patients with invasive listeriosis were included, of which 21 patients received gentamicin combination treatment and 15 received monotherapy. The mean age-adjusted Charlson Comorbidity Index (aaCCI) value was lower in the gentamicin combination treatment group (5.4 vs. 7.4). Neurolisteriosis was more common in the gentamicin group (81% vs. 20%). The 90-day mortality was with significantly lower in the gentamicin combination treatment group (10%) compared to the monotherapy group (60%). Multivariable cox regression analysis, adjusted for a propensity score computed based on neurolisteriosis, aaCCI and sex, revealed a significantly reduced hazard ratio of 0.07 (95% CI: 0.01–0.53, p = 0.01) for 90-day mortality for the gentamicin combination treatment.

Conclusion

This retrospective study highlights the benefit of gentamicin combination treatment in reducing the 90-day mortality rate among patients with invasive listeriosis. The high prevalence of monotherapy in this study cohort raises concerns about the adequacy of antibiotic therapy in clinical practice.
Literature
3.
go back to reference Scobie A, Kanagarajah S, Harris RJ, Byrne L, Amar C, Grant K, et al. Mortality risk factors for listeriosis - A 10 year review of non-pregnancy associated cases in England 2006–2015. J Infect. 2019;78:208–14.CrossRefPubMed Scobie A, Kanagarajah S, Harris RJ, Byrne L, Amar C, Grant K, et al. Mortality risk factors for listeriosis - A 10 year review of non-pregnancy associated cases in England 2006–2015. J Infect. 2019;78:208–14.CrossRefPubMed
5.
go back to reference Rivera-Izquierdo M, Galicia-García MD, Láinez-Ramos-Bossini AJ, Redruello-Guerrero P, Fernández-Martínez NF. Risk factors associated with early mortality after recovery from severe listeriosis: a multicentre 17-year longitudinal study. Infection. 2023;51:181–91.CrossRefPubMed Rivera-Izquierdo M, Galicia-García MD, Láinez-Ramos-Bossini AJ, Redruello-Guerrero P, Fernández-Martínez NF. Risk factors associated with early mortality after recovery from severe listeriosis: a multicentre 17-year longitudinal study. Infection. 2023;51:181–91.CrossRefPubMed
6.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed
7.
go back to reference Kvistholm Jensen A, Simonsen J, Ethelberg S. Use of Proton Pump inhibitors and the risk of listeriosis: a Nationwide Registry-based Case-Control Study. Clin Infect Dis. 2017;64:845–51.PubMed Kvistholm Jensen A, Simonsen J, Ethelberg S. Use of Proton Pump inhibitors and the risk of listeriosis: a Nationwide Registry-based Case-Control Study. Clin Infect Dis. 2017;64:845–51.PubMed
8.
go back to reference Amaya-Villar R, García-Cabrera E, Sulleiro-Igual E, Fernández-Viladrich P, Fontanals-Aymerich D, Catalán-Alonso P, et al. Three-year multicenter surveillance of community-acquired Listeria monocytogenes meningitis in adults. BMC Infect Dis. 2010;10:324.CrossRefPubMedPubMedCentral Amaya-Villar R, García-Cabrera E, Sulleiro-Igual E, Fernández-Viladrich P, Fontanals-Aymerich D, Catalán-Alonso P, et al. Three-year multicenter surveillance of community-acquired Listeria monocytogenes meningitis in adults. BMC Infect Dis. 2010;10:324.CrossRefPubMedPubMedCentral
9.
go back to reference Bertino JS, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993;167:173–9.CrossRefPubMed Bertino JS, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993;167:173–9.CrossRefPubMed
10.
go back to reference Tian L, Huang C, Fu W, Gao L, Mi N, Bai M, et al. Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota. Front Pharmacol. 2023;14:1217306.CrossRefPubMedPubMedCentral Tian L, Huang C, Fu W, Gao L, Mi N, Bai M, et al. Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota. Front Pharmacol. 2023;14:1217306.CrossRefPubMedPubMedCentral
11.
go back to reference Rückert-Eheberg I-M, Nolde M, Ahn N, Tauscher M, Gerlach R, Güntner F, et al. Who gets prescriptions for Proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010–2018. Eur J Clin Pharmacol. 2022;78:657–67.CrossRefPubMed Rückert-Eheberg I-M, Nolde M, Ahn N, Tauscher M, Gerlach R, Güntner F, et al. Who gets prescriptions for Proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010–2018. Eur J Clin Pharmacol. 2022;78:657–67.CrossRefPubMed
Metadata
Title
Gentamicin combination treatment is associated with lower mortality in patients with invasive listeriosis: a retrospective analysis
Authors
Jan P. Sutter
Lorenz Kocheise
Jan Kempski
Martin Christner
Dominic Wichmann
Hans Pinnschmidt
Stefan Schmiedel
Ansgar W. Lohse
Samuel Huber
Thomas Theo Brehm
Publication date
04-07-2024
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2024
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-024-02330-w

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar